EKSO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EKSO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ekso Bionics Holdings has the Growth Rank of 7.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Growth Rank distribution charts can be found below:
* The bar in red indicates where Ekso Bionics Holdings's Growth Rank falls into.
Thank you for viewing the detailed overview of Ekso Bionics Holdings's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Lathan Corinna | director | 140 KENDRICK STREET, NEEDHAM MA 02494 |
Jerome Wong | officer: Interim CFO | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Scott G. Davis | officer: President & COO | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Steven Sherman | director | |
Jason C Jones | officer: VP of Product Development | EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
John Glenn | officer: Chief Financial Officer | 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577 |
William R Shaw | officer: See Remarks | 1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804 |
Rhonda A. Wallen | director | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Mary Ann Cloyd | director | 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059 |
Combest Development (hong Kong) Ltd | 10 percent owner | ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077 |
Jack Peurach | director, officer: Chief Executive Officer | 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804 |
Thomas A Schreck | director | 10240 BUBB RD, CUPERTINO CA 95014 |
Puissance Capital Management (gp) Llc | 10 percent owner | 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Theodore T Wang | director, 10 percent owner | C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Christian Babini | officer: VP of Sales, Americas | C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804 |
From GuruFocus
By GlobeNewswire • 08-30-2024
By GuruFocus Research • 07-30-2024
By Marketwired • 10-28-2024
By Marketwired • 02-24-2025
By Marketwired • 02-10-2025
By GuruFocus News • 03-04-2025
By GuruFocus Research • 04-30-2024
By Marketwired • 01-13-2025
By GuruFocus News • 02-14-2025
By Marketwired • 11-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.